News & Resources

Overview

Webcast ImageWebcast
Q2 2016 Orexigen Therapeutics, Inc. Earnings Conference Call (Live)
08/04/16 at 2:00 p.m. PT
Q2 2016 Orexigen Therapeutics, Inc. Earnings Conference Call
Thursday, August 4, 2016 2:00 p.m. PT  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar

Corporate Profile

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. Orexigen’s first medicine, Contrave® (naltrexone HCl and bupropion HCl extended release), was approved in the United States in September 2014 and has become the most prescribed branded obesity medication since June 2015. In Europe the drug has been approved under the brand name Mysimba™ (naltrexone HCl/ bupropion HCl prolonged relMore >>

Stock Quote

OREX (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$3.35
Change (%) Stock is Down 0.03 (0.89%)
Volume56,936
Jul 29, 2016 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote

Recent News

More >>
DateTitle 
07/21/16Orexigen Therapeutics to Provide Business Update and Discuss Second Quarter 2016 Financial Results on August 4, 2016Printer Friendly Version
07/08/16Orexigen Therapeutics Announces Stockholder Approval of All Proposals at 2016 Annual Meeting and Reverse Stock SplitPrinter Friendly Version
06/22/16Orexigen Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)Printer Friendly Version
06/08/16Orexigen Therapeutics Reports Favorable Markman Ruling in Contrave® Patent LitigationPrinter Friendly Version

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.